摘要
近年来,肝癌的药物治疗取得显著进展,成为中晚期肝癌病人延长生存的重要手段。其中仑伐替尼联合程序性死亡因子1(PD-1)抗体的临床探索在中国非常普遍。部分不可切除或中晚期肝癌病人在接受仑伐替尼联合PD-1抗体治疗的过程中出现肿瘤缩小,从不可切除肝癌转变为可切除肝癌。此文从中国肝癌的现状、不可切除肝癌的转化治疗历史和近年来药物治疗的进步着手,对不可切除或中晚期肝癌转化切除研究中需要进一步探索的问题进行了评述。
In recent years,systemic therapy for hepatocellular carcinoma(HCC)has made significant advances to prolong survival for advanced HCC patients.Among emerging systemic therapies,combined therapy of lenvatinib and anti-PD1 antibodies has been commonly applied in China.Tumor regression occurs in some unresectable or advanced HCC patients receiving combined therapy of lenvatinib and anti-PD1 antibodies,converting unresectable HCC into resectable HCC.This review started with the current status of HCC in China,traced the history of conversion therapy for unresectable HCC,followed recent advances of systemic therapy in recent years and addressed the outstanding issues of conversion surgery for unresectable or advanced HCC.
作者
孙惠川
Sun Huichuan(Department of Liver Cancer Surgery,Affiliated Zhongshan Hospital,Fudan University,Shanghai 200032,China)
出处
《腹部外科》
2021年第2期85-87,共3页
Journal of Abdominal Surgery
关键词
肝癌
不可切除
转化切除
Hepatocellular carcinoma
Unresectable hepatocellular carcinoma
Conversion surgery
作者简介
孙惠川,博士,主任医师,教授,博士生导师,主要从事肝肿瘤外科的基础与临床方面的研究,Email:sun.huichuan@zs-hospital.sh.cn。
